Dr James Mackay speaks about the increased requirement for genetic testing within oncology. There is currently an unacceptable level of variation in the turnaround times for these tests and this variation must be addressed before patients can receive equal treatment opportunities irrespective of their geographic location. Dr Mackay explains how improvements are being guided by patient feedback and discusses possibility of using PARP inhibitors as chemoprevention for patients with a BRCA genetic mutation.